Human Life Cord specialize in allogeneic cell therapy, applying umbilical cord derived mesenchymal stromal cells (MSCs) that are able to differentiate into a variety of cell types. Learn more about the Tokyo-based organization in this installment of our Let’s Interview Series.
Venture Valuation (VV) interviewed President and CEO, Mr. Harata Masamitsu.
Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?